DNA and RNA methylation are essential epigenetic modifications that play a crucial role in regulating gene expression and cellular processes. Methylation is also significant in viral infections, influencing various stages of the viral life cycle and immune evasion. In this study, we investigated the antiviral potential of sinefungin, a potent methyltransferase inhibitor, against Herpes Simplex Virus 1 (HSV-1) and SARS-CoV-2. The cytotoxic effect of sinefungin was evaluated on VERO-76 cells by exposing them to concentrations ranging from 12.5 to 200 μg/mL for 24 h. The MTT assay results indicated that sinefungin reduced cell viability by approximately 21.7% at the highest concentration tested, with a CC50 above 200 μg/mL. Our results demonstrated that sinefungin exhibited significant antiviral activity against both HSV-1 and SARS-CoV-2, with IC50 values of 49.5 ± 0.31 μg/mL for HSV-1 and 100.1 ± 2.61 μg/mL for SARS-CoV-2. These results suggest that sinefungin may be a promising therapeutic candidate for treating viral infections, particularly those involving methylation-dependent processes.

The Impact of the S-Adenosylmethionine Analogue Sinefungin on Viral Life Cycles

Dell'Annunziata F.;Capuano N.;De Prisco M.;Folliero V.;Franci G.
2025

Abstract

DNA and RNA methylation are essential epigenetic modifications that play a crucial role in regulating gene expression and cellular processes. Methylation is also significant in viral infections, influencing various stages of the viral life cycle and immune evasion. In this study, we investigated the antiviral potential of sinefungin, a potent methyltransferase inhibitor, against Herpes Simplex Virus 1 (HSV-1) and SARS-CoV-2. The cytotoxic effect of sinefungin was evaluated on VERO-76 cells by exposing them to concentrations ranging from 12.5 to 200 μg/mL for 24 h. The MTT assay results indicated that sinefungin reduced cell viability by approximately 21.7% at the highest concentration tested, with a CC50 above 200 μg/mL. Our results demonstrated that sinefungin exhibited significant antiviral activity against both HSV-1 and SARS-CoV-2, with IC50 values of 49.5 ± 0.31 μg/mL for HSV-1 and 100.1 ± 2.61 μg/mL for SARS-CoV-2. These results suggest that sinefungin may be a promising therapeutic candidate for treating viral infections, particularly those involving methylation-dependent processes.
2025
File in questo prodotto:
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11386/4921963
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus 0
  • ???jsp.display-item.citation.isi??? 0
social impact